Finoriq research workspace
Zentalis Pharmaceuticals, Inc. (ZNTL) SEC Filings & Filing Highlights
Zentalis Pharmaceuticals, Inc. develops azenosertib, which is in a Phase 3 clinical trial for the. Review ZNTL SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
- Company
- Zentalis Pharmaceuticals, Inc. (ZNTL)
- Ticker
- ZNTL
- Market Cap
- $356.6M
- Latest Price
- $5.01
- Industry
- Biotech & Pharma
Zentalis Pharmaceuticals, Inc. (ZNTL) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Zentalis Pharmaceuticals, Inc. (ZNTL).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesOn June 16, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At th... | 8-K5.07 | 2026-06-18 |
| Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc....Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six... | 8-K5.02 | 2026-05-27 |
| In an all-comer PROC population across all four dose cohorts, the following clinical activity w...On May 21, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) announced that data from Part 1 of the Phase 1b MUIR trial will be presente... | 8-K8.01 | 2026-05-21 |
| On May 21, 2026, Zentalis Pharmaceuticals, Inc. issued the press release furnished as Exhibit 9...On May 21, 2026, Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) issued the press release furnished as Exhibit 99.1 to this Cu... | 8-K7.01 | 2026-05-21 |
| Beginning May 12, 2026, spokespersons of the Company plan to present the information in the Cor...Beginning May 12, 2026, spokespersons of the Company plan to present the information in the Corporate Presentation furnished as Exhibit 99.... | 8-K7.01 | 2026-05-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.